Biofrontera Inc. (BFRI) Revenue History
Annual and quarterly revenue from 2019 to present
BFRI Revenue Over Time (2019–2025)
BFRI Revenue Growth History
5 of 6 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- -28.0%
- FY2021 revenue growth
- +27.9%
- FY2022 revenue growth
- +19.0%
- FY2023 revenue growth
- +18.8%
- FY2024 revenue growth
- +9.5%
- FY2025 revenue growth
- +11.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $10.1M | +17.4% |
| Q4 2025 | $17.1M | +36.2% |
| Q3 2025 | $7.0M | -22.5% |
| Q2 2025 | $9.0M | +15.2% |
| Q1 2025 | $8.6M | +8.7% |
| Q4 2024 | $12.6M | +18.5% |
| Q3 2024 | $9.0M | +1.3% |
| Q2 2024 | $7.8M | +34.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2023)
BFRI's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
BFRI Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 22, 2026, Biofrontera Inc. (BFRI) generated trailing twelve-month (TTM) revenue of $43.2 million, reflecting strong growth of +17.4% year-over-year. The most recent quarter (Q1 2026) recorded $10.1 million in revenue, down 41.0% sequentially.
Historical Growth Trajectory
BFRI's 5-year compound annual growth rate (CAGR) stands at +17.2%, indicating consistent double-digit revenue growth. The 3-year CAGR of +13.3% is below the 5-year average, signalling a growth deceleration in recent years. Biofrontera Inc.'s highest annual revenue of $41.7 million was recorded in 2025, an all-time high.
Revenue by Segment
BFRI's revenue is primarily driven by Government and Payor Rebates (58%), Co-pay Assistance Program (31%), and Returns (10%). With over half of revenue concentrated in Government and Payor Rebates, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including DERM (+15.0% YoY), PRGO (-3.6% YoY), and NVCR (+8.5% YoY) — BFRI has outperformed the peer group in revenue growth. Compare BFRI vs DERM →
BFRI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BFRICurrent | $43M | +17.4% | +17.2% | -21.9% | |
 DERM | $62M | +15.0% | +6.8% | -13.2% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 GDRX | $797M | -1.2% | +7.7% | 11.0% | |
 SKIN | $301M | -8.2% | +20.4% | -6.9% |
BFRI Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $41.7M | +11.8% | $32.8M | 78.7% | $-9,148,000 | -21.9% |
| 2024 | $37.3M | +9.5% | $18.7M | 50.1% | $-17,210,000 | -46.1% |
| 2023 | $34.1M | +18.8% | $16.6M | 48.8% | $-22,677,000 | -66.6% |
| 2022 | $28.7M | +19.0% | $13.5M | 47.0% | $-18,581,000 | -64.8% |
| 2021 | $24.1M | +27.9% | $11.4M | 47.1% | $-25,201,000 | -104.6% |
| 2020 | $18.8M | -28.0% | $9.8M | 51.9% | $-9,606,000 | -51.0% |
| 2019 | $26.2M | - | $13.8M | 52.6% | $-14,922,000 | -57.0% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BFRI — Frequently Asked Questions
Quick answers to the most common questions about buying BFRI stock.
Is BFRI's revenue growth accelerating or slowing?
BFRI revenue growth is accelerating. TTM revenue reached $43M, up +17.4% year-over-year — ahead of the 5-year CAGR of +17.2%. This indicates the business is expanding faster than its historical baseline.
What is BFRI's revenue history from 2019 to 2026?
Biofrontera Inc. (BFRI) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $43M, growing at +17.4% YoY. The 5-year CAGR is +17.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BFRI's long-term revenue growth rate (CAGR)?
Biofrontera Inc.'s 5-year revenue CAGR of +17.2% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +17.4% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BFRI.
Why does BFRI's quarterly revenue fluctuate?
BFRI quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Biofrontera Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is BFRI's revenue distributed by segment?
BFRI reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BFRI's revenue compare to industry peers?
Biofrontera Inc. (BFRI) with TTM revenue of $43M and +17.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.